Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.beha.2024.101540 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis" [Crit. Rev. Oncol./Hematol. 201 (2024) 104416].
Crit Rev Oncol Hematol
October 2024
Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain.
Corrigendum to "Identification of sensitive endpoints for the assessment of phthalates induced reproductive and developmental toxicity: A literature mining study" [Food Chem. Toxicol. 188, June (2024)].
Food Chem Toxicol
September 2024
Department of Toxicology, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China; Key Laboratory of State Administration of Traditional Chinese Medicine for Compatibility Toxicology, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China; Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China. Electronic address:
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].
Eur Urol
September 2024
Sutter Cancer Center (accruals under Radiological Associates of Sacramento), Sacramento, CA, USA.
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer.
Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of androgen deprivation therapy (ADT) + external beam radiation therapy (EBRT) + docetaxel with ADT + EBRT.
Design, Setting, And Participants: High-risk localized prostate cancer patients (>50% of patients had Gleason 9-10 disease) were prospectively randomized to 2 yr of ADT + EBRT or ADT + EBRT + six cycles of docetaxel.
Corrigendum to "Endpoint selection and evaluation in hematology studies" [Best Pract Res Clin Haematol 36 (2023) 101479].
Best Pract Res Clin Haematol
March 2024
Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. Electronic address:
Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials.
Front Cardiovasc Med
February 2024
Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
[This corrects the article DOI: 10.3389/fcvm.2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!